Nurofen painkillers to be pulled over misleading claims
Some types of Nurofen painkillers will be pulled from sale after claims that they treat specific types of pain were found to be misleading.
The Australian Competition and Consumer Commission took manufacturer Reckitt Benckiser to the Federal Court over products in its Nurofen specific-pain range, which are advertised as being specially formulated to treat back pain, period pain, migraines or tension headaches.
The court found that, in reality, each of the products had exactly the same active ingredient – 342 milligrams of ibuprofen lysine – and that none were any better at treating one type of pain than other products in the range.
"Nurofen specific-pain products were being sold at retail prices almost double that of Nurofen’s standard ibuprofen products and the general pain relief products of its competitors," ACCC chairman Rod Sims said. Sydney Morning Herald – Read more…
The Australian Competition and Consumer Commission took manufacturer Reckitt Benckiser to the Federal Court over products in its Nurofen specific-pain range, which are advertised as being specially formulated to treat back pain, period pain, migraines or tension headaches.
The court found that, in reality, each of the products had exactly the same active ingredient – 342 milligrams of ibuprofen lysine – and that none were any better at treating one type of pain than other products in the range.
"Nurofen specific-pain products were being sold at retail prices almost double that of Nurofen’s standard ibuprofen products and the general pain relief products of its competitors," ACCC chairman Rod Sims said. Sydney Morning Herald – Read more…
Recent Posts
